Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation
    source: pixabay.com

    Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation

    Medical studies are crucial players in the journey to develop new and more efficacious treatment options for patients with rare diseases. On June 10, 2021, Vertex Pharmaceuticals Incorporated ("Vertex") shared…

    Continue Reading Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation
    Phase 2 PRA023 Trial for UC Begins
    source: pixabay.com

    Phase 2 PRA023 Trial for UC Begins

    Clinical trials are important research tools to help understand the safety, efficacy, and tolerability of potential treatments. According to a news release from July 19, 2021, biotechnology company Prometheus Biosciences,…

    Continue Reading Phase 2 PRA023 Trial for UC Begins
    Mepsevii for MPS VII Reimbursement Approval Available in Spain
    source: pixabay.com

    Mepsevii for MPS VII Reimbursement Approval Available in Spain

    According to a recent news release from biopharmaceutical company Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), the company's therapy Mepsevii (vestronidase alfa) was approved in Spain for reimbursement. The entire reimbursement process takes…

    Continue Reading Mepsevii for MPS VII Reimbursement Approval Available in Spain